Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03756038
Other study ID # PRO18090064
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 25, 2019
Est. completion date March 27, 2019

Study information

Verified date February 2020
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this proposal, the investigators will determine if a single dose of oral lorazepam reduces distress, pain severity, and need for opiate analgesics both in the ED and in the acute recovery period after discharge. The investigators will compare the lorazepam arm to a placebo arm.


Description:

The investigators will enroll 120 medically stable adult patients who present to two emergency departments with a physical injury (< 24 hours ago) and a chief complaint of pain.

The investigators will randomly assign subjects using a blocked randomization schedule to either: 1) a single dose of oral lorazepam (1mg), or 2) oral placebo. Emergency department providers and patients will be blind to treatment allocation.

All participants will complete measures of negative affect and pain scores at baseline, and and 1 and 2 hours post-study drug administration. The investigators will record any analgesics administered in the emergency department until discharge. Patients will also undergo quantitative sensory testing in the Emergency Department at baseline, and after study drug administration. At 14-days post-discharge, the investigators will measure summary reports of pain, mood, and analgesic medication used.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date March 27, 2019
Est. primary completion date March 27, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Adults between the ages of 18-65

- Sustained a physical injury with a pain score = 5 on the numeric rating scale [NRS] from 0- 10 with anchors of 0 = "no pain" and 10 = "worst pain imaginable"

- Expected to be in the ED for at least 2 hours, in a private treatment room

- Ownership of a cell phone with text messaging capabilities

- Emergency Department admission assessment confirmed subject is not suicidal.

Exclusion Criteria:

- Non-English speaking

- Not medically suitable for lorazepam per treating MD (e.g. medical condition where benzodiazepines are contraindicated or may be unsafe)

- Not alert and oriented

- Active psychosis, self-injury, suicidal/homicidal intentions on initial evaluation by treating team

- Seeking treatment due to a mental health or substance use disorder

- History of chronic opioid use

- Prescribed opioid or benzodiazepine use within the past 24 hours

- Alcohol use within the past 12 hours or medical history of alcoholism.

- Clinical indication for open-label benzodiazepine administration in the ED.

- Any use of recreational narcotics throughout lifetime

- Sensitivity or allergy or intolerance to opioids or benzodiazepines

- Current neurological disease (e.g., multiple sclerosis, stroke, brain tumor, seizure disorder, etc.)

- Prisoner

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebos
In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
Lorazepam
The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.

Locations

Country Name City State
United States UPMC Mercy Hospital Pittsburgh Pennsylvania
United States UPMC Presbyterian Hospital Pittsburgh Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Maria Pacella The UPMC Mercy Emergency Medicine Fund, University of Pittsburgh Physicians

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Severity in the Emergency Department: Numeric Rating Scale Pain Numeric Rating Scale (on a scale from 0, no pain to 10, worst pain imaginable) The item is anchored to pain intensity "right now" at 60 minutes post-study drug administration
Secondary Negative Affect in the Emergency Department Positive and Negative Affect Schedule (PANAS)-We will use the 10 items of the Negative Affect Scale; each of these items are scored on a Likert Scale ranging from 1 (very slightly/not at all) to 5 (extremely). The responses for each of the 10 items are summed to create the Negative Affect Score; scores may range from 10-50, with lower scores representing lower scores of negative affect. The 10 items of the Negative Affect Scale are anchored to mood "right now" at 60 minutes post-study drug administration.
See also
  Status Clinical Trial Phase
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT03825549 - A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing N/A
Completed NCT05995912 - Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain Phase 2
Recruiting NCT05589246 - Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure N/A
Recruiting NCT05572190 - Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects Phase 1
Terminated NCT04716413 - Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment Phase 4
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Not yet recruiting NCT06317844 - Examination of Psychological and Physiological Pathways Linking Gratitude and Pain N/A
Withdrawn NCT02957097 - Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures Phase 4
Terminated NCT02599870 - Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures N/A
Completed NCT02565342 - Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery Phase 4
Completed NCT02380989 - Integrative Ayurveda Healing Relieves Minor Sports Injury Pain Phase 2
Completed NCT02984098 - 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose Phase 4
Completed NCT02489630 - Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department Phase 4
Completed NCT03107338 - Preventive Treatment of Pain After Dental Implant Surgery Phase 4
Completed NCT02817477 - Intranasal Ketamine for Acute Traumatic Pain Phase 4